Tuesday, December 17, 2019 10:59:05 PM
Whal'
AMARIN knows that 2019 will produce $425-440 sales revenue.... all conferences JT has attended, all CC's they have had since submittal of SDNA, all Medical shows JT has been on,etc, have questioned him concerning him about potential API supply to cover increased scripts.... take into account just last weeks 8o,ooo scripts, approval of VASCEPA starting MONDAY 12-16,2019, Approvals from AHA,ACA,ALA,ADA,etc, sales to be gained from scripts sold each week to Lovasa/generics coming to AMARIN..... NOBODY expects sales of $650-700 for 2020.... even the analysts reporting stated that 2020 projections are low..... and sales people in AMARIN have said it is to low... THE MARKET EXPECTS CLOSE TO 1 BIL. AMARIN (DID'T) lowered guidance, they gave A low guidance .... can you tell the difference???
Monday,downward pressure on price was lower guidance and after 4:00 o'clock after the market closed then information came out concerning a patent settlement, continuing downward pressure today (tues)... two separate situations piggybacking on each other....
Made a perfect BEAR raid by short's/mm....
AMARIN knows that 2019 will produce $425-440 sales revenue.... all conferences JT has attended, all CC's they have had since submittal of SDNA, all Medical shows JT has been on,etc, have questioned him concerning him about potential API supply to cover increased scripts.... take into account just last weeks 8o,ooo scripts, approval of VASCEPA starting MONDAY 12-16,2019, Approvals from AHA,ACA,ALA,ADA,etc, sales to be gained from scripts sold each week to Lovasa/generics coming to AMARIN..... NOBODY expects sales of $650-700 for 2020.... even the analysts reporting stated that 2020 projections are low..... and sales people in AMARIN have said it is to low... THE MARKET EXPECTS CLOSE TO 1 BIL. AMARIN (DID'T) lowered guidance, they gave A low guidance .... can you tell the difference???
Monday,downward pressure on price was lower guidance and after 4:00 o'clock after the market closed then information came out concerning a patent settlement, continuing downward pressure today (tues)... two separate situations piggybacking on each other....
Made a perfect BEAR raid by short's/mm....
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
